IRIS
BUTI, Sebastiano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 15.183
NA - Nord America 13.633
EU - Europa 7.945
SA - Sud America 3.053
AF - Africa 906
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 9
Totale 40.758
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.218
SG - Singapore 6.882
VN - Vietnam 2.532
CN - Cina 2.274
BR - Brasile 2.271
IT - Italia 1.761
IE - Irlanda 1.575
HK - Hong Kong 1.406
SE - Svezia 1.258
FR - Francia 662
NL - Olanda 636
ZA - Sudafrica 577
DE - Germania 565
IN - India 353
AR - Argentina 279
GB - Regno Unito 274
BD - Bangladesh 251
FI - Finlandia 228
RU - Federazione Russa 214
AT - Austria 209
CA - Canada 168
IQ - Iraq 158
TR - Turchia 150
MX - Messico 146
JP - Giappone 134
EC - Ecuador 133
IR - Iran 126
ID - Indonesia 120
KR - Corea 106
CO - Colombia 98
PK - Pakistan 96
PH - Filippine 86
UZ - Uzbekistan 80
ES - Italia 79
VE - Venezuela 79
UA - Ucraina 73
BE - Belgio 68
PL - Polonia 68
MA - Marocco 65
PY - Paraguay 61
MY - Malesia 56
CI - Costa d'Avorio 54
TH - Thailandia 53
SA - Arabia Saudita 52
CL - Cile 50
EG - Egitto 46
TN - Tunisia 45
CZ - Repubblica Ceca 39
TW - Taiwan 39
UY - Uruguay 28
KE - Kenya 27
JO - Giordania 26
LT - Lituania 26
PE - Perù 26
AU - Australia 25
AE - Emirati Arabi Uniti 24
AL - Albania 24
AZ - Azerbaigian 23
BO - Bolivia 23
DK - Danimarca 21
DO - Repubblica Dominicana 21
NP - Nepal 20
IL - Israele 19
KZ - Kazakistan 19
RO - Romania 18
ET - Etiopia 16
PS - Palestinian Territory 16
PA - Panama 15
CH - Svizzera 14
DZ - Algeria 14
BG - Bulgaria 13
OM - Oman 13
EE - Estonia 12
LB - Libano 12
PT - Portogallo 12
RS - Serbia 12
BH - Bahrain 11
CR - Costa Rica 11
HN - Honduras 10
HU - Ungheria 10
LU - Lussemburgo 10
NG - Nigeria 10
QA - Qatar 10
SN - Senegal 10
AO - Angola 9
BY - Bielorussia 9
GR - Grecia 9
HR - Croazia 9
JM - Giamaica 9
SV - El Salvador 9
KW - Kuwait 8
MD - Moldavia 7
KG - Kirghizistan 6
TT - Trinidad e Tobago 6
BB - Barbados 5
GT - Guatemala 5
LV - Lettonia 5
LY - Libia 5
XK - ???statistics.table.value.countryCode.XK??? 5
AM - Armenia 4
Totale 40.664
Salva come PNG Salva come JPEG
Città #
Singapore 3.283
Chandler 1.909
Ashburn 1.849
San Jose 1.621
Dublin 1.558
Hong Kong 1.345
Dallas 1.150
Santa Clara 1.006
Ho Chi Minh City 817
Boardman 618
Hanoi 598
Beijing 565
Johannesburg 513
Lauterbourg 447
Princeton 298
Los Angeles 280
New York 229
Milan 224
Shanghai 224
São Paulo 215
Munich 200
Vienna 161
Parma 160
Bologna 128
Helsinki 128
Council Bluffs 125
Rome 125
Ann Arbor 122
Hefei 116
Nuremberg 107
Haiphong 103
Des Moines 102
Da Nang 100
Frankfurt am Main 94
Moscow 93
Tehran 92
Columbus 88
Tokyo 84
Rio de Janeiro 80
Buffalo 78
Turku 78
Wilmington 69
Tashkent 67
London 66
Chicago 65
Atlanta 58
Montreal 58
Orem 57
Baghdad 55
Marseille 55
Abidjan 54
Curitiba 53
Warsaw 53
Brussels 51
Chennai 51
Bremen 50
Jakarta 50
Quito 47
Biên Hòa 46
Belo Horizonte 43
Dhaka 43
Boston 42
Amsterdam 41
The Dalles 41
Seattle 40
Verona 40
Brasília 39
Brooklyn 39
Denver 39
Phoenix 39
Toronto 39
Guayaquil 38
Modena 38
Guangzhou 37
Hải Dương 37
Mexico City 37
Pune 37
Stockholm 36
Seoul 35
Tianjin 35
Genoa 33
Poplar 33
San Francisco 33
Lahore 31
Can Tho 30
Istanbul 30
Dearborn 29
New Delhi 29
Asunción 28
Jacksonville 27
Nanjing 27
Houston 26
Ninh Bình 26
North Bergen 26
Amman 25
Bangkok 25
Buenos Aires 25
Florence 25
Kuala Lumpur 25
Medellín 25
Totale 23.491
Salva come PNG Salva come JPEG
Nome #
LBA77 Fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: Preliminary results of the randomized phase II TACITO trial 265
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 217
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 214
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab 202
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 198
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors 189
PREDICTIVE AND PROGNOSTIC VALUE OF CLINICAL AND MOLECULAR FEATURES IN PATIENTS UNDERGOING PULMONARY METASTASECTOMY FROM RENAL CELL CARCINOMA 180
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 180
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 176
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non–clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study 175
External validation of the novel prognostic Meet-URO score in Metastatic Renal Cell Carcinoma on First Line Immune-combination therapy. - Proceedings from the Second International Urology Cancer Summit, 27th September, Portsmouth, UK 175
New hormonal agents and integrated strategies for non-metastatic, hormone-sensitive prostate carcinoma: the orphan setting?—a narrative review 174
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 174
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 170
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 167
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 164
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 162
Early primary tumor response in metastatic RCC patients treated with immune checkpoint inhibitors-based combinations 162
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 160
ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients 157
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 153
The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes 152
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 152
Review on radiological evolution of COVID-19 pneumonia using computed tomography 150
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors 149
Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 dataset 148
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors 147
Changes in lymphocyte count induced by repeated cycles with low-dose interleukin-2 and interferon-α in 146 patients with renal cell carcinoma. 147
Chronically administered immunotherapy with low-dose IL-2 and IFN-α in metastatic renal cell carcinoma: A feasible option for patients with a good prognostic profile 147
91 Circulating lipid profile as a prognostic factor in patients with advanced solid tumors treated with immune checkpoint inhibitors 145
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 144
Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma 144
Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade 143
Fecal microbiota transplantation to improve efficacy of immune checkpoint inhibitors in renal cell carcinoma (TACITO trial) 142
Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity 141
READY: Real-world data from an Italian compassionate use program of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC) 140
Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinoma 140
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 140
1901P Specific dynamic changes of peripheral blood immune profile (PBIP) associate with clinical response to nivolumab (NIVO) in patients (pts) with metastatic renal cell carcinoma (mRCC): The I-RENE trial (meet-URO 8) 140
Immunotherapy options in metastatic renal cell cancer: Where we are and where we are going 140
Unraveling the link between cholesterol and immune system in cancer: From biological mechanistic insights to clinical evidence. A narrative review 137
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 137
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 137
Clinical parameters for first-line immuno-combinations choice in metastatic renal cell carcinoma (mRCC) patients (pts): the Meet-URO 33 study 136
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 135
Monitoring cfDNA in plasma and in other liquid biopsies of advanced EGFR mutated NSCLC patients: A pilot study and a review of the literature 135
Adjusted Skeletal Muscle Index (aSMI) correlates with outcome in metastatic Renal Cancer Cell (mRCC) patients (pts) treated with first line (1L) immunotherapy (IT) 134
Molecular classification using Lund University algorithm and clinical correlations in muscle-invasive bladder cancer: Insights from a retrospective study 134
Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients (Scientific Reports, (2019), 9, 1, (13218), 10.1038/s41598-019-49250-6) 133
Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs) 131
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2) 130
Combined standard immunosuppression and immune checkpoint inhibition for BKPyV+ metastatic renal cell carcinoma of the graft in a kidney transplant recipient with chronic rejection: a case report 128
1599P Clinical predictors of 30-day mortality in hospitalized patients with lung cancer: A retrospective single-center observational study 127
2125P Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study 126
The Role of CT Imaging in Characterization of Small Renal Masses 125
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 125
7 Tamoxifen vs tamoxifen plus 13-cis-retinoic acid vs tamoxifen plus interferon α-2° as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomized multicentre trial 125
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 124
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The practice study 124
Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy: Interim results from the phase 2 ARCADIA trial. 123
Differential diagnosis of COVID-19 at the chest computed tomography scan: A review with special focus on cancer patients 122
External Validation of the GRade, Age, Nodes and Tumor (GRANT) Score for Patients with Surgically Treated Papillary Renal Cell Carcinoma 121
P254 REAl-world Data from an Italian Compassionate Use Program (CUP) of avelumab first- Line Maintenance (1LM) for locallY advanced or metastatic Urothelial Carcinoma (la/mUC): Outcomes from the READY study in patients (pts) with low tumor burden 118
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab 118
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy 118
A wide skull osteolytic metastasis in advanced breast cancer 117
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors 115
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score 115
1895P Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15) 115
Abscopal effect after hypofractionated radiotherapy in metastatic renal cell carcinoma pretreated with pazopanib 115
Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-α for metastatic renal cell cancer 115
The effect of concomitant drugs on oncological outcomes in patients treated with immunotherapy for metastatic urothelial carcinoma: a narrative review 114
Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: A case report 114
The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab 113
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 113
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients 113
External validation of the GRade, Age, Nodes and Tumor (GRANT) score for patients with surgically treated papillary renal cell carcinoma. - Proceedings from the Second International Urology Cancer Summit, 27th September, Portsmouth, UK. 113
Takotsubo syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab plus axitinib 112
LA PRATICA CLINICA - Everolimus nel carcinoma renale papillare 112
Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario 111
1462P Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a) 111
BOLERO-3 results: Pharmacological activity or pharmacokinetic effect? 111
Cabozantinib in metastatic renal cell carcinoma: Latest findings and clinical potential 111
BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients 110
Real world analysis of peritoneal metastasis from renal cell carcinoma: Meet-Uro 27 study 109
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study 109
1476P Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study 108
1716P Primary resistance to front-line immune-based combinations in patients with advanced renal cell carcinoma (ARON-1) 108
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 108
Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy 108
THE ROLE OF BLOOD CHOLESTEROL QUALITY IN PATIENTS WITH ADVANCED CANCER RECEIVING IMMUNE CHECKPOINT INHIBITORS 107
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations 107
Role of Chemotherapy With Gemcitabine Plus 5-fluorouracil and Chemoimmunotherapy in Metastatic Renal Cell Cancer (mRCC) 107
1981P Cabozantinib plus durvalumab in patients with advanced and chemotherapy-treated urothelial carcinoma (UC) and variant histology (VH): An open-label, phase II, single-arm proof-of-concept trial: ARCADIA study. Subgroup analysis for bone metastasis 106
Potential ROle of hypovitaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): a prospective observational study. 106
Retroperitoneal cystoadenocarcinoma: A case report with a literature review 106
Avelumab Maintenance for Urothelial Carcinoma 106
Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? 104
Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study 104
Overall survival (OS) results in phase II Trial of Cabozantinib (CABO) plus durvalumab (DURVA) in patients with urothelial carcinoma (UC) or non- UC variant histologies (VH) after platinum chemotherapy (ARCADIA). 103
Totale 13.624
Salva come PNG Salva come JPEG
Categoria #
all - tutte 160.308
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 160.308
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202147 0 0 0 0 0 0 0 0 0 19 16 12
2021/20221.466 9 10 13 30 5 117 319 100 61 25 100 677
2022/20236.059 710 740 558 380 457 586 80 316 1.925 27 203 77
2023/20242.659 135 225 103 109 290 542 204 125 178 154 189 405
2024/202510.042 157 697 754 408 903 1.145 418 456 1.254 1.204 727 1.919
2025/202620.580 1.633 1.890 3.179 2.016 2.965 1.081 2.523 854 2.758 1.681 0 0
Totale 41.391